Shanghai Allist - Public Comps and Valuation Multiples

Shanghai Allist Overview

About Shanghai Allist

Shanghai Allist Pharmaceuticals Co Ltd is an innovative drug company in the field of cancer treatment.

Founded

2004

HQ

Employees

n/a

Website

allist.com.cn

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $665M

LTM EBITDA $222M

EV

$6.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Shanghai Allist Financials

As of September 2025, Shanghai Allist reported last 12-month revenue of $665M and EBITDA of $222M.

In the same period, Shanghai Allist generated $638M in LTM gross profit and $243M in net income.

See Shanghai Allist valuation multiples based on analyst estimates

Shanghai Allist P&L

In the most recent fiscal year, Shanghai Allist reported revenue of $499M and EBITDA of $232M.

Shanghai Allist expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Shanghai Allist valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$665M	XXX	$499M	XXX	XXX	XXX
Gross Profit	$638M	XXX	$479M	XXX	XXX	XXX
Gross Margin	96%	XXX	96%	XXX	XXX	XXX
EBITDA	$222M	XXX	$232M	XXX	XXX	XXX
EBITDA Margin	33%	XXX	47%	XXX	XXX	XXX
EBIT	$279M	XXX	$216M	XXX	XXX	XXX
EBIT Margin	42%	XXX	43%	XXX	XXX	XXX
Net Profit	$243M	XXX	$201M	XXX	XXX	XXX
Net Margin	36%	XXX	40%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Shanghai Allist including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $665M. EBITDA for the last twelve months was $222M. In the most recent fiscal year, Shanghai Allist achieved $499M in revenue and $232M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$665M	Analyst estimates available to subscribers	$499M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$638M	Analyst estimates available to subscribers	$479M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	95.8% gross margin	Analyst estimates available to subscribers	96.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$222M	Analyst estimates available to subscribers	$232M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	33.4% EBITDA margin	Analyst estimates available to subscribers	46.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$279M	Analyst estimates available to subscribers	$216M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	41.9% EBIT margin	Analyst estimates available to subscribers	43.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$243M	Analyst estimates available to subscribers	$201M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	36.5% net profit margin	Analyst estimates available to subscribers	40.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Shanghai Allist

This financial data table provides comprehensive performance metrics for Shanghai Allist, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Shanghai Allist generated $665M in revenue over the last twelve months.
The company achieved $222M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $638M.
Net income over the last twelve months reached $243M.

Fiscal Year Performance

In the most recent fiscal year, Shanghai Allist reported $499M in total revenue.
Fiscal year EBITDA was $232M.
The company maintained a gross profit margin of 96.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was 46.6%.
Net profit margin reached 40.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Shanghai Allist. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Shanghai Allist Stock Performance

Shanghai Allist has current market cap of CNY 47.6B (or $6.7B), and EV of CNY 43.8B (or $6.1B).

Market Cap Evolution

Shanghai Allist Stock Data

As of October 17, 2025, Shanghai Allist's stock price is CNY 106 (or $15).

See Shanghai Allist trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$6.1B	$6.7B	XXX	XXX	XXX	XXX	$0.54

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Shanghai Allist Valuation Multiples

Shanghai Allist's trades at 12.3x EV/Revenue multiple, and 26.4x EV/EBITDA.

See valuation multiples for Shanghai Allist and 15K+ public comps

Shanghai Allist Financial Valuation Multiples

As of October 17, 2025, Shanghai Allist has market cap of $6.7B and EV of $6.1B.

Equity research analysts estimate Shanghai Allist's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Shanghai Allist has a P/E ratio of 27.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$6.7B	XXX	$6.7B	XXX	XXX	XXX
EV (current)	$6.1B	XXX	$6.1B	XXX	XXX	XXX
EV/Revenue	9.2x	XXX	12.3x	XXX	XXX	XXX
EV/EBITDA	27.6x	XXX	26.4x	XXX	XXX	XXX
EV/EBIT	22.1x	XXX	28.5x	XXX	XXX	XXX
EV/Gross Profit	9.6x	XXX	n/a	XXX	XXX	XXX
P/E	27.5x	XXX	33.3x	XXX	XXX	XXX
EV/FCF	n/a	XXX	33.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Shanghai Allist Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Shanghai Allist Margins & Growth Rates

Shanghai Allist's last 12 month revenue growth is 23%

Shanghai Allist's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Shanghai Allist's rule of 40 is 57% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Shanghai Allist's rule of X is 90% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Shanghai Allist and other 15K+ public comps

Shanghai Allist Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	23%	XXX	30%	XXX	XXX	XXX
EBITDA Margin	33%	XXX	47%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	57%	XXX	69%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	90%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	26%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	9%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	53%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial